Bank of New York Mellon Corp Increases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bank of New York Mellon Corp boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.3% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 698,253 shares of the biopharmaceutical company's stock after acquiring an additional 8,990 shares during the quarter. Bank of New York Mellon Corp owned about 0.64% of Regeneron Pharmaceuticals worth $442,853,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in REGN. Marietta Wealth Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 30.2% during the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after purchasing an additional 2,501 shares in the last quarter. Pamalican Asset Management Ltd purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $4,915,000. Intact Investment Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $356,000. Rhenman & Partners Asset Management AB increased its stake in shares of Regeneron Pharmaceuticals by 11.4% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock valued at $30,956,000 after purchasing an additional 4,457 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in shares of Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after purchasing an additional 814,713 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on REGN. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and cut their price target for the company from $700.00 to $580.00 in a research note on Friday, May 30th. Bank of America cut their price target on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research note on Thursday, April 17th. Royal Bank Of Canada lowered Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price target for the company. in a research note on Friday, May 30th. Citigroup cut their price objective on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research note on Monday, June 2nd. Finally, Robert W. Baird cut their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $822.58.

Regeneron Pharmaceuticals Stock Up 0.9%

REGN traded up $4.83 during mid-day trading on Wednesday, reaching $552.58. 831,354 shares of the stock were exchanged, compared to its average volume of 1,139,169. The company has a 50 day moving average price of $547.51 and a two-hundred day moving average price of $623.07. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. The stock has a market capitalization of $59.66 billion, a PE ratio of 14.07, a price-to-earnings-growth ratio of 1.98 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter in the prior year, the firm posted $9.55 earnings per share. The company's revenue was down 3.7% on a year-over-year basis. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.64%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.